Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | CASR | P41180 | 9/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27659859 | 0.85 | CASR (0.53) | MRGPRX4NPC1RAB9AL3MBTL1CASR | |
| SCHEMBL8564808 | 0.80 | AR (0.43) | NPC1RAB9AGAAALDH1A1KDM4E | |
| SCHEMBL13485291 | 0.80 | NPC1 (0.60) | NPC1RAB9AGAAALDH1A1KDM4E | |
| SCHEMBL16951877 | 0.80 | CYP1A2 (0.43) | NPC1RAB9AL3MBTL1GAAALDH1A1 | |
| SCHEMBL5007730 | 0.79 | NPC1 (0.55) | MRGPRX4NPC1RAB9AL3MBTL1CASR | |
| SCHEMBL8387204 | 0.79 | MRGPRX4 (0.49) | MRGPRX4NPC1RAB9AL3MBTL1CASR | |
| SCHEMBL11508991 | 0.79 | TLR8 (0.52) | MRGPRX4NPC1RAB9AL3MBTL1CASR | |
| SCHEMBL23087507 | 0.79 | PDE3A (0.43) | NPC1RAB9AL3MBTL1GAATLR8 | |
| SCHEMBL5102958 | 0.79 | L3MBTL1 (0.50) | NPC1RAB9AL3MBTL1CYP2D6ALDH1A1 | |
| SCHEMBL2416172 | 0.79 | ALDH1A1 (0.58) | NPC1RAB9AL3MBTL1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | MRGPRX4 2724/4885NPC1 1929/4885RAB9A 2399/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | MRGPRX4 3006/4885NPC1 1856/4885RAB9A 3196/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | MRGPRX4 3306/4885NPC1 1741/4885RAB9A 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.